Literature DB >> 30431366

The acute respiratory distress syndrome: pathophysiology, current clinical practice, and emerging therapies.

Matthias Derwall1,2, Lukas Martin1,2, Rolf Rossaint1,2.   

Abstract

INTRODUCTION: More than fifty years after the first description of acute respiratory distress syndrome (ARDS) by Ashbaugh and colleagues, no specific treatment of the underlying pathophysiological processes is available. The current therapeutic regime is comprised of supportive measures such as lung protective ventilation, restrictive fluid management, paralyzing drugs, and prone positioning. Although vast improvements have been made in ARDS-treatment during the last five decades, mortality among patients with severe ARDS remains at an unacceptable rate of 45%. Areas covered: This article reviews the evolution of the currently used definition, established pathophysiological mechanism, highlights the current best clinical practice to treat ARDS, gives a brief outlook on cutting edge trends in ARDS research and closes with an expert opinion on the subject. Expert commentary: Individualizing the provided measures to specific genotypes is the key challenge in ARDS research today. The ongoing digital revolution will help to individualize ARDS-treatment and will therefore presumably improve survival and quality of life.

Entities:  

Keywords:  Acute respiratory distress syndrome; cell therapy; lung protective ventilation; nitric oxide; prone positioning

Mesh:

Year:  2018        PMID: 30431366     DOI: 10.1080/17476348.2018.1548280

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  11 in total

1.  Phosphodiesterase 4 mediates interleukin-8-induced heterologous desensitization of the β2 -adrenergic receptor.

Authors:  Thomas C Rich; Silas J Leavesley; Angela P Brandon; Cilina A Evans; S Vamsee Raju; Brant M Wagener
Journal:  FASEB J       Date:  2021-10       Impact factor: 5.834

Review 2.  Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms.

Authors:  Yu-Qiong He; Can-Can Zhou; Lu-Yao Yu; Liang Wang; Jiu-Ling Deng; Yu-Long Tao; Feng Zhang; Wan-Sheng Chen
Journal:  Pharmacol Res       Date:  2020-09-29       Impact factor: 7.658

3.  Long non-coding RNA SNHG5 suppresses the development of acute respiratory distress syndrome by targeting miR-205/COMMD1 axis.

Authors:  Jiao Wang; Yang Zhang; Lihai Zhang
Journal:  Mol Cell Biochem       Date:  2020-11-10       Impact factor: 3.396

Review 4.  Effects of mesenchymal stromal cell-derived extracellular vesicles in acute respiratory distress syndrome (ARDS): Current understanding and future perspectives.

Authors:  Yue Su; Haiyan Guo; Qinghua Liu
Journal:  J Leukoc Biol       Date:  2021-05-06       Impact factor: 4.962

Review 5.  Nanotherapeutics in the treatment of acute respiratory distress syndrome.

Authors:  Pragya Prasanna; Shweta Rathee; Arun Upadhyay; Sulakshana Sulakshana
Journal:  Life Sci       Date:  2021-03-27       Impact factor: 6.780

6.  Combination of pseudoephedrine and emodin ameliorates LPS-induced acute lung injury by regulating macrophage M1/M2 polarization through the VIP/cAMP/PKA pathway.

Authors:  Wen-Ba Wang; Jing-Tao Li; Yi Hui; Jie Shi; Xu-Yan Wang; Shu-Guang Yan
Journal:  Chin Med       Date:  2022-02-05       Impact factor: 5.455

7.  Knockdown of circ_0001679 alleviates lipopolysaccharide-induced MLE-12 lung cell injury by regulating the miR-338-3p/ mitogen-activated protein kinase 1 axis.

Authors:  Shenggui Lu; Xinmiao Wu; Shuai Xin; Jing Zhang; Hanying Lin; Yu Miao; Yixin Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 8.  Advances in the use of exosomes for the treatment of ALI/ARDS.

Authors:  Chang Liu; Kun Xiao; Lixin Xie
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

Review 9.  Progress in preclinical studies of macrophage autophagy in the regulation of ALI/ARDS.

Authors:  Chang Liu; Kun Xiao; Lixin Xie
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

10.  A Peptide Inhibitor of Peroxiredoxin 6 Phospholipase A2 Activity Significantly Protects against Lung Injury in a Mouse Model of Ventilator Induced Lung Injury (VILI).

Authors:  Aron B Fisher; Chandra Dodia; Shampa Chatterjee
Journal:  Antioxidants (Basel)       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.